UCB's $2 Billion Investment in Georgia: A New Era for Biopharmaceutical Manufacturing

Belgian pharmaceutical company UCB has announced plans to invest $2 billion in a new biologics manufacturing facility in Gwinnett County, Georgia, marking its first U.S. plant. This facility, which will create approximately 330 jobs, is part of UCB's strategy to expand its presence in the U.S. market and enhance its manufacturing capabilities. The plant will be located within the Rowen Foundation's 2,000-acre science and learning campus, designed to foster innovation and collaboration in the life sciences sector.

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing FacilityFiercePharmaBelgian drugmaker UCB to invest $2B in suburban Atlanta plant, adding 330 jobs

UCB's investment is expected to generate an estimated total economic impact of $5 billion for the region. The facility will span 460,000 square feet and is designed to produce biologics, which are complex drugs derived from living cells. The project is anticipated to take six to seven years for design and construction, with Gwinnett County officials committing $174 million in incentives, including property tax breaks and infrastructure improvements.

Belgian drugmaker UCB to invest $2B in suburban Atlanta plant, adding 330 jobs

The choice of Gwinnett County aligns with UCB's goal to be part of a growing life sciences community. The site is strategically located near key research institutions such as Georgia Tech and the University of Georgia, which are integral to UCB's innovation pipeline. UCB CEO Jean-Christophe Tellier emphasized the company's long-term commitment to the U.S., stating that the investment reflects confidence in UCB's growth and the region's potential as a hub for biopharmaceutical innovation.

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing FacilityFiercePharma

Governor Brian P. Kemp highlighted the significance of UCB's investment as one of the largest in Georgia's history, reinforcing the state's position as a leader in the life sciences industry. "UCB’s announcement is a significant milestone for our life sciences industry," he stated. Gwinnett County Board of Commissioners Chairwoman Nicole Love Hendrickson expressed enthusiasm for UCB's decision, noting it aligns with the county's vision of establishing Rowen as a center for collaboration and discovery.

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility

While the investment is largely viewed positively, some critics have raised concerns about the reliance on incentives to attract large corporations. Questions remain regarding the long-term sustainability of such investments and their impact on local communities.

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility

There are no significant conflicting reports regarding the investment details; however, the timeline for job creation and the exact nature of the roles to be filled remain somewhat vague. Further clarity on these aspects may emerge as the project progresses.

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility

• “This decision reflects our confidence in UCB’s long-term growth and our deep-rooted commitment to the United States,” — Jean-Christophe Tellier, CEO of UCB

Belgian drugmaker UCB to invest $2B in suburban Atlanta plant, adding 330 jobs

• “UCB’s announcement is also a significant milestone for our life sciences industry, representing one of the largest investments in state history and establishing both the Rowen facility and Georgia as a true hub of innovation in this field.” — Governor Brian P. Kemp

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility

• “An investment of this magnitude was exactly what we envisioned when we committed to establishing Rowen as a hub for collaboration and discovery.” — Nicole Love Hendrickson, Chairwoman, Gwinnett County Board of Commissioners

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility

• “To add manufacturing really builds out this full value chain,” — Taco van Tiel, UCB's U.S. Chief

FiercePharma

As UCB moves forward with its plans, the company will begin the design and construction phases of the facility, with a focus on integrating advanced technologies such as AI and robotics. The project is expected to further solidify Georgia's reputation as a key player in the biopharmaceutical manufacturing landscape.

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility